The Convergence Frontier: Integrating Machine Learning and High Performance Quantum Computing for Next-Generation Drug Discovery
Organizations: Qubit Pharmaceuticals, Advanced Research Department, 75014 Paris, France · Qubit Pharmaceuticals Inc, Advanced Research Department, Chicago, IL, USA · Sorbonne Université, Laboratoire de Chimie Théorique, UMR 7616 CNRS, 75005 Paris, France
Abstract
Integrating quantum mechanics into drug discovery marks a decisive shift from empirical trial-and-error toward quantitative precision. However, the prohibitive cost of ab initio molecular dynamics has historically forced a compromise between chemical accuracy and computational scalability. This paper identifies the convergence of High-Performance Computing (HPC), Machine Learning (ML), and Quantum Computing (QC) as the definitive solution to this bottleneck. While ML foundation models, such as FeNNix-Bio1, enable quantum-accurate simulations, they remain tethered to the inherent limits of classical data generation. We detail how High-Performance Quantum Computing (HPQC), utilizing hybrid QPU-GPU architectures, will serve as the ultimate accelerator for quantum chemistry data. By leveraging Hilbert space mapping, these systems can achieve true chemical accuracy while bypassing the heuristics of classical approximations. We show how this tripartite convergence optimizes the drug discovery pipeline, spanning from initial system preparation to ML-driven, high-fidelity simulations. Finally, we position quantum-enhanced sampling as the beyond GPU frontier for modeling reactive cellular systems and pioneering next-generation materials.
Figures & tables
| Method | ||
|---|---|---|
| tUCCSDT [ 67 ] | 1. Fermionic singles/doubles, . 3. Energy, Pauli strings. 5. Global, non-convex. 7. Small systems, moderate correlation. | 2. Fixed. 4. Pre-determined. 6. Weak. 8. Chemically inspired, lacks flexibility. |
| ADAPT [ 70 ] | 1. Any, up to . 3. Energy, Pauli strings. 5. Global, non-convex. 7. Small systems, moderate/high correlation. | 2. Adaptive, operator-wise. 4. On-the-fly energy gradient. 6. Weak. 8. Barren-plateaus resilience. |
| GGA [ 71 ] | 1. Any. 3. Energy, Pauli strings. 5. Sequential, deterministic update. 7. Small systems, weak correlation | 2. Adaptive, operator-wise. 4. On-the-fly energy line-search. 6. Moderate/strong. 8. High trainability, low expressivity. |
| Overlap-ADAPT [ 72 ] | 1. Any. 3. Overlap, observable. 5. Global, convex. 7. Strong correlation levels. | 2. Adaptive, operator-wise. 4. On-the-fly overlap gradient. 6. Strong. 8. Needs accurate target state. |
| MB-ADAPT [ 69 ] | 1. Minimal complete pool, . 3. Energy, Pauli strings. 5. Global, non-convex. 7. Large systems, all correlation levels. | 2. Adaptive, batch of operators. 4. On-the-fly energy gradients. 6. Intermediate. 8. Reduced gradient costs w.r.t ADAPT. |
| NI-DUCC(MCPs) [ 68 , 69 ] | 1. Minimal complete pool, . 3. Energy, Pauli strings. 5. Global, non-convex. 7. Large systems, all correlation levels. | 2. Fixed, layered. 4. Pre-determined. 6. Intermediate. 8. Very expressive ansatz. |
| Real-space basis | Molecular-Orbital basis | |
|---|---|---|
| Quantization | First quantization | Second quantization |
| Qubit count | ; logarithmic in basis | ; no explicit particle dependence |
| Hamiltonian terms | Typically ; diagonal Coulomb term | Typically ; |
| Quantum algorithms | QPE, QEVE (FTQC) | VQE (NISQ), QPE (FTQC) |
| Spatial resolution tricks | Adaptive grids, Transcorrelated Hamiltonian | Adaptive basis sets (SABS), orbital rotations |
| Maximum Logical Qubits | ||||
|---|---|---|---|---|
| H100 GPUs | Total Memory | Hyperion-1 | Hyperion-2 (MPS) | Hyperion-2 (Partitioned) |
| 1 | 24 | 30 | 28 | |
| 4 | - | 32 | 30 | |
| 8 | 28 | - | 31 | |
| 16 | - | 36* | 32 | |
| 64 | - | - | 36 | |
| Software | Max Qubits | Accuracy | SV | MPS | GPUs |
| Hyperion-1 (SV) 1 | 32 | Exact | ✓ | ✓ | |
| Hyperion-2 (Partitioned SV/MPS) 1 | 36 (40 1 ) | Locally Exact+Locally bounded | ✓ | ✓ | ✓ |
| Hyperion-2 MPS 1 | 36 | Globally bounded | ✓ | ✓ | |
| quantumlib qsim SV (Google) 2 | 12 | Exact | ✓ | ||
| cuStateVec SV (NVIDIA) 3 | 32 | Exact | ✓ | ✓ | |
| cuTensorNet MPS (NVIDIA) 4 | 36 | Globally bounded | ✓ | ✓ |
| Component | Description |
|---|---|
| Model Nature | A foundation machine learning model designed for accurate, reactive atomistic simulations of biological systems. |
| Architectural Variants | Consists of FeNNix-Bio1(S) (light-weight, high-throughput) and FeNNix-Bio1(M) (heavier, higher accuracy). |
| Training Data | Trained on the Ignis dataset ( 2.23M conformations) derived exclusively from synthetic DFT quantum chemistry data |
| Energy Decomposition | Total energy is decomposed into atomic contributions using a Mixture-of-Experts (MoE) multilayer perceptron. |
| Charge Modeling | Employs multi-Qeq embedding to globally distribute total charge, enabling non-local differentiation of charge states. |
| Receptive Field | Uses two-layer equivariant message-passing with a total receptive field of 11Å , comparable to traditional force fields. |
| Application Domain | Specific Description | Notable Performance / Result |
|---|---|---|
| Liquid Water Properties | Calculation of radial distribution functions, density, and enthalpy of vaporization. | Reaches the quality of accurate polarizable models while outperforming other foundation models at lower cost. |
| Ions in Solution | Study of the behavior of and ions in a water box. | Achieves agreement with polarizable force fields. |
| Hydration Free Energies (HFEs) | Prediction of HFEs for over 600 molecules in the Freesolv dataset. | Provides sub-kcal/mol accuracy and converges at least 60 times faster than other foundation models. |
| Protein Folding | Study of the reversible folding of the Chignolin protein (CLN025). | Recovers folded, misfolded, and unfolded states; first time achieved with a foundation ML model. |
| Protein-Ligand Complexes | MD simulation of complexes such as the Benzamidine-Trypsin complex. | Maintains a well-preserved binding mode over several nanoseconds of trajectory. |
| Absolute Binding Free Energy | Calculation of standard binding free energy for Phenol and Benzene to Lysozyme. | Obtains values close to experimental results, such as kcal/mol for benzene-lysozyme. |
| Dataset Component | Description & Scope | Quantum Level of Theory |
|---|---|---|
| Core Base Set | 2.1 million molecular conformations including SPICE2 and 100K ANI-2X configurations selected via active learning. | DFT: B97M-D3BJ with ccECP and aug-cc-pVTZ basis sets. |
| Solvated Ions | 28,000 conformations of biologically relevant ions (e.g., Na, Cl, Zn) in varying water cluster sizes (2–10 molecules). | DFT: B97M-D3BJ-ccECP. Finetuned with AMOEBA-03 force predictions for monovalent ions. |
| Intermolecular Data | 64,080 molecule-water dimers sampled from the Freesolv database to capture subtle solvation energies. | DFT: Interaction energies computed as the difference between dimer and monomer sum. |
| Physical Limits | Synthetic data for isolated atoms and highly distorted water molecules to ensure correct dissociation behavior. | DFT: Adjusted to match the formation energy of the chosen functional. |
| High-Accuracy Subset | 40,000 configurations (20,251 with full forces) extracted for “beyond DFT” refinement. | QMC: Diffusion Monte Carlo (DMC) operating in the infinite-basis set limit. |
| Strong Correlation | 2,000 configurations specifically targeting significant electronic correlation effects. | Multideterminant QMC: DMC with Selected-CI wavefunctions (1.4M determinants). |
| Feature | Standard ADAPT-VQE | ADAPT-VQE + DBBSC |
|---|---|---|
| Primary Goal | Minimize energy within a fixed, finite basis set. | Approach the Complete-Basis-Set (CBS) limit using small basis sets. |
| Basis Set Requirements | Requires large basis sets (e.g., cc-pVTZ) for high-accuracy predictions. | Achieves high accuracy using minimal basis sets (e.g., STO-3G, 6-31G). |
| Qubit Resources | Qubit count scales linearly with the large basis size, often requiring hundreds of qubits. | Drastically reduced; enables accurate simulations with as few as 10–30 qubits. |
| Correction Strategy | None; results are limited by basis-set truncation errors. | Hybrid: Combines quantum solver with classical density-functional and HF corrections. |
| Implementation | Purely variational quantum algorithm. | Can be applied a posteriori (Strategy 1) or self-consistently (Strategy 2). |
| Convergence Rate | Slow convergence with respect to basis-set size. | Accelerated convergence to the CBS limit through self-consistent improvement. |
| System | Method / Basis | N qubits | Energy (Ha) | vs CBS (mHa) |
|---|---|---|---|---|
| H 2 O | 6-31G (ADAPT-VQE) | 24 | -76.11989 | 258 |
| V5Z-11 with SC(ADAPT+PBE)+ HF** | 30 | -76.33570 | 42.42 | |
| cc-pVTZ (FCI) | 114 | -76.33250 | 46 | |
| FCI (CBS) | 400 † | -76.37812 | ||
| LiH | 6-31G (ADAPT-VQE) | 20 | -7.99800 | 27 |
| V5Z-10 with SC(ADAPT+PBE)+ HF* | 28 | -8.02540 | 0.58 |
| Molecule | (QEB) | (qubit) | |
|---|---|---|---|
| 6-31G | 24 | 12657 | 5862 |
| V5Z-11 | 30 | 12647 | 5858 |
| LiH | |||
| 6-31G | 20 | 511 | 242 |
| V5Z-10 | 28 | 1083 | 506 |
| Cpd. | Total Time (ns) | LAO Speedup | |||||||
|---|---|---|---|---|---|---|---|---|---|
| (Ours) | LAO a | FL b | OO c | vs. FL | vs. OO | ||||
| L1 | 192 | 840 | 4000 | 4.4x | 20.8x | ||||
| L2 | 192 | 840 | 5600 | 4.4x | 29.2x | ||||
| L3 | 192 | 840 | 4000 | 4.4x | 20.8x | ||||
| L4 | 192 | 840 | 4800 | 4.4x | 25.0x | ||||
| L5 | 192 | 840 | 4000 | 4.4x | 20.8x | ||||
| Method | Calculations | Total Sim. (ns) | Net Savings |
|---|---|---|---|
| LAO (Ours) | 11 Ligands 3 Repeats | 6,336 | – |
| Fixed- (FL) | 11 Ligands 3 Repeats | 27,720 | 21,384 ns saved |
| oneOPES (OO) | 11 Ligands (Single Runs) | 57,600 | 51,264 ns saved |
| System | Challenge Type | Method | Sampling/Edge | RMSE | Speedup/Edge | |
|---|---|---|---|---|---|---|
| PWWP1 | Charge-Changing | Dual-LAO | 24 ns a | 0.46 | 0.62 | 30x |
| (Ionic Change) | FEP+ [ 194 ] | 960 ns b [ 193 ] | 1.14 | 0.79 | – | |
| BRD4 | Buried Water | Dual-LAO | 24 ns a | 0.64 | 0.76 | 15x |
| (Displacement) | FEP+ [ 193 ] | 480 ns c | 2.05 | 0 | – | |
| P38 | Fragment-like | Dual-LAO | 24 ns a | 0.82 | 0.77 | 15x |
| (Large Shift) | FEP+ [ 193 ] | 480 ns c | 0.90 | 0.56 | – |
| System | No. Edges | FEP+ Total (ns) | Dual-LAO Total (ns) | Net Savings (ns) |
|---|---|---|---|---|
| PWWP1 | 30 3 Rep. | 46,080 | 2160 | 93,920 |
| BRD4 | 11 3 Rep. | 15,840 | 990 | 14,850 |
| P38 | 7 3 Rep. | 10,080 | 630 | 9,450 |
| CHK1 | 8 3 Rep. | 15,360 | 720 | 14,640 |
| Total | 56 3 Rep. | 86,360 | 4,500 | 82,860 |
| Measured : | 0 | 0.5 | 1 |
|---|---|---|---|
| H2-1 | 12 | 444 | 29 |
| Helios | 8 | 464 | 16 |
| Expected | 0 | 500 | 0 |
Drug Discovery
Drug discovery identifies, designs, and tests molecules that can safely affect disease biology.
See all 164 papers